{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:11:22Z","timestamp":1770891082881,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T00:00:00Z","timestamp":1564876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T00:00:00Z","timestamp":1564876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41390-019-0523-4","type":"journal-article","created":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T07:02:14Z","timestamp":1564902134000},"page":"892-896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Valganciclovir prophylaxis delays onset of EBV viremia in high-risk pediatric solid organ transplant recipients"],"prefix":"10.1038","volume":"87","author":[{"given":"Sawsan","family":"Albatati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Haubrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soren","family":"Gantt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom D.","family":"Blydt-Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,4]]},"reference":[{"key":"523_CR1","doi-asserted-by":"publisher","first-page":"13984","DOI":"10.1128\/JVI.79.22.13984-13992.2005","volume":"79","author":"GK Hong","year":"2005","unstructured":"Hong, G. K. et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J. Virol. 79, 13984\u201313992 (2005).","journal-title":"J. Virol."},{"key":"523_CR2","doi-asserted-by":"crossref","unstructured":"Yang, J. et al. Characterization of Epstein-Barr virus\u2013infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 96, 4055\u20134063 (2000).","DOI":"10.1182\/blood.V96.13.4055"},{"key":"523_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/00007890-200208150-00013","volume":"74","author":"RD Holmes","year":"2002","unstructured":"Holmes, R. D. et al. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation 74, 367\u2013372 (2002).","journal-title":"Transplantation"},{"key":"523_CR4","doi-asserted-by":"crossref","unstructured":"Allen, U. D., Preiksaitis, J. K. & AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am. J. Transplant. 13 (Suppl 4), 107\u2013120 (2013).","DOI":"10.1111\/ajt.12104"},{"key":"523_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1155\/2002\/634318","volume":"13","author":"U Allen","year":"2002","unstructured":"Allen, U. et al. Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment. Can. J. Infect. Dis. 13, 89\u201399 (2002).","journal-title":"Can. J. Infect. Dis."},{"key":"523_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.5414\/CN106572","volume":"76","author":"M Ishihara","year":"2011","unstructured":"Ishihara, M. et al. Epstein-Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipients. Clin. Nephrol. 76, 40\u201348 (2011).","journal-title":"Clin. Nephrol."},{"key":"523_CR7","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/S0031-3955(03)00127-5","volume":"50","author":"M Green","year":"2003","unstructured":"Green, M. & Webber, S. Posttransplantation lymphoproliferative disorders. Pediatr. Clin. North Am. 50, 1471\u20131491 (2003).","journal-title":"Pediatr. Clin. North Am."},{"key":"523_CR8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1128\/CMR.00006-09","volume":"23","author":"ML Gulley","year":"2010","unstructured":"Gulley, M. L. & Tang, W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin. Microbiol. Rev. 23, 350\u2013366 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"523_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jcv.2010.03.016","volume":"48","author":"B G\u00e4rtner","year":"2010","unstructured":"G\u00e4rtner, B. & Preiksaitis, J. K. EBV viral load detection in clinical virology. J. Clin. Virol. 48, 82\u201390 (2010).","journal-title":"J. Clin. Virol."},{"key":"523_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1399-0012.2012.01608.x","volume":"26","author":"CJ Holman","year":"2012","unstructured":"Holman, C. J. et al. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin. Transpl. 26, 741\u2013747 (2012).","journal-title":"Clin. Transpl."},{"key":"523_CR11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/lt.21498","volume":"14","author":"L Hierro","year":"2008","unstructured":"Hierro, L. et al. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transpl. 14, 1185\u20131193 (2008).","journal-title":"Liver Transpl."},{"key":"523_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/jac\/dki240","volume":"56","author":"E Gershburg","year":"2005","unstructured":"Gershburg, E. & Pagano, J. S. Epstein-Barr virus infections: prospects for treatment. J. Antimicrob. Chemother. 56, 277\u2013281 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"523_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","volume":"11","author":"R Reshef","year":"2011","unstructured":"Reshef, R. et al. Reduction of immunosuppression as initial therapy for post-transplantation lymphoproliferative disorder. Am. J. Transplant. 11, 336\u2013347 (2011).","journal-title":"Am. J. Transplant."},{"key":"523_CR14","unstructured":"Franke, A. J. et al. Association of allograft rejection with reduction of immunosuppression for post-transplant lymphoproliferative disorder: analysis of a 20-year single-institutional experience. J. Clin. Oncol. 35, e19047 (2017)."},{"key":"523_CR15","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1681\/ASN.2009111188","volume":"21","author":"JM Smith","year":"2010","unstructured":"Smith, J. M. et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J. Am. Soc. Nephrol. 21, 1579\u20131586 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"523_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1432-2277.2012.01485.x","volume":"25","author":"B Hocker","year":"2012","unstructured":"Hocker, B. et al. (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl. Int. 25, 723\u2013731 (2012).","journal-title":"Transpl. Int."},{"key":"523_CR17","doi-asserted-by":"crossref","unstructured":"Darenkov, I. A. M. et al. Reduced incidence of epstein-barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 64, 848\u2013852 (1997).","DOI":"10.1097\/00007890-199709270-00010"},{"key":"523_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S1053-2498(01)00407-7","volume":"21","author":"MA Malouf","year":"2002","unstructured":"Malouf, M. A. et al. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J. Heart Lung Transplant. 21, 547\u2013554 (2002).","journal-title":"J. Heart Lung Transplant."},{"key":"523_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1378\/chest.116.5.1273","volume":"116","author":"SM Levine","year":"1999","unstructured":"Levine, S. M. et al. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients. Chest 116, 1273\u20131277 (1999).","journal-title":"Chest"},{"key":"523_CR20","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1111\/j.1600-6143.2005.01115.x","volume":"5","author":"DP Funch","year":"2005","unstructured":"Funch, D. P., Walker, A. M., Schneider, G., Ziyadeh, N. J. & Pescovitz, M. D. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am. J. Transplant. 5, 2894\u20132900 (2005).","journal-title":"Am. J. Transplant."},{"key":"523_CR21","doi-asserted-by":"publisher","unstructured":"Cameron, B. M., Kennedy, S. E., Rawlinson, W. D. & Mackie, F. E. The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children. Pediatr. Transplant. \nhttps:\/\/doi.org\/10.1111\/petr.12816\n\n (2017).","DOI":"10.1111\/petr.12816"},{"key":"523_CR22","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1164\/ajrccm.154.6.8970360","volume":"154","author":"RM Aris","year":"1996","unstructured":"Aris, R. M. et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am. J. Respir. Crit. Care Med. 154, 1712\u20131717 (1996).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"523_CR23","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/01.tp.0000202724.07714.a2","volume":"81","author":"A Humar","year":"2006","unstructured":"Humar, A. et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 81, 856\u2013861 (2006).","journal-title":"Transplantation"},{"key":"523_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(07)70040-2","volume":"8","author":"G Opelz","year":"2007","unstructured":"Opelz, G., Daniel, V., Naujokat, C., Fickenscher, H. & Dohler, B. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol. 8, 212\u2013218 (2007).","journal-title":"Lancet Oncol."},{"key":"523_CR25","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients (2009). Am. J. Transplant. 9 (Suppl 3), S1\u2013S155 (2009).","DOI":"10.1111\/j.1600-6143.2009.02834.x"},{"key":"523_CR26","unstructured":"R. C. Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, 2015)."},{"key":"523_CR27","doi-asserted-by":"publisher","first-page":"e13382","DOI":"10.1111\/petr.13382","volume":"23","author":"G Paulsen","year":"2019","unstructured":"Paulsen, G. et al. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal valganciclovir prophylaxis. Pediatr. Transplant. 23, e13382 (2019).","journal-title":"Pediatr. Transplant."},{"key":"523_CR28","unstructured":"Valcyte\u00ae Prescribing Information. Genentech USA, Inc., South San Francisco, CA, (2017)."},{"key":"523_CR29","unstructured":"Ville, S. et al. Impact of antiviral prophylaxis in adults Epstein\u2013Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study. Transpl. Int. 31, 484\u2013494 (2018)."},{"key":"523_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/TP.0b013e3181761659","volume":"86","author":"LJ Swinnen","year":"2008","unstructured":"Swinnen, L. J. et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2b, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 86, 215\u2013222 (2008).","journal-title":"Transplantation"},{"key":"523_CR31","unstructured":"Rabot, N. et al. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality. Transpl. Int. 27, 956\u2013965 (2014)."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41390-019-0523-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-019-0523-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-019-0523-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:27:40Z","timestamp":1684618060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-019-0523-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,4]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["523"],"URL":"https:\/\/doi.org\/10.1038\/s41390-019-0523-4","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,4]]},"assertion":[{"value":"23 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.G. receives research funding and consulting fees from Merck, GSK, VBI, and Meridian Biosciences. T.D.B.-H. receives research funding from Astellas. A.W. has received consulting fees or honoraria from Merck, AVIR Pharma, Pendopharm, and Astellas. A.S. has received payment for \u201cconducting or overseeing statistical analyses.\u201d The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}